Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOR106 in moderate to severe atopic dermatitis
NCT03568071Phase 2Terminated
- Sponsor
- Galapagos NV
- Start
- Apr 2018
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of MOR106 in atopic dermatitis (AD), sponsored by Galapagos NV. Started Apr 2018; status: terminated.
02
Drugs
MOR106
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03568071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03568071.